Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Relapsed/Refractory Multiple Myeloma
NCT00227682Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2004
- Primary completion
- Feb 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in multiple myeloma (MM), sponsored by OHSU Knight Cancer Institute. Started Jun 2004; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00227682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227682.